ZION Clinical Research Study – COPD
About the Study
ZION is a clinical research study for adults with Chronic Obstructive Pulmonary Disease (COPD).
This study will test an investigational injectable drug called solrikitug to learn about its safety, effectiveness, and tolerability (side effects) in people living with COPD.
What Is the Study Drug?
The investigational medication, solrikitug, aims to help reduce inflammation caused by COPD.
Two dose levels are being evaluated. The study drug is given as an injection under the skin.
Study Duration
Participation lasts approximately 32 weeks and includes:
-
Screening Period (up to 4 weeks): Review and sign the Informed Consent Form (ICF) and undergo screening tests to confirm eligibility.
-
Treatment Period (12 weeks): Receive either the study drug or placebo every 4 weeks.
-
Follow-Up Period (16 weeks): Attend health assessments so the research team can monitor your condition.
Throughout the study, participants will continue their daily maintenance COPD medications.
What Is a Placebo?
A placebo looks like the study drug but does not contain any active ingredient.
This allows researchers to compare results between groups to determine whether improvements are due to the study drug.
Who Can Join?
You may qualify if you:
✔ Are 40–75 years old
✔ Have been diagnosed with COPD for at least 12 months
✔ Use two or more daily maintenance inhaled medications
Additional eligibility requirements apply.
Participation Details
Participation is voluntary — you can withdraw at any time.
You will receive study-related care and monitoring at no cost.
You may also be compensated for time and travel to required study visits.
